Effect of infliximab on sight-threatening panuveitis in Behçet's disease.
about
Behçet's disease: from Hippocrates to the third millenniumBehçet's disease: a new target for anti-tumour necrosis factor treatmentRemission of Behcet's disease with anti-tumor necrosis factor monoclonal antibody therapy: a case reportBehçet's diseaseA Clinical Picture of the Visual Outcome in Adamantiades-Behçet's DiseaseTransscleral sustained vasohibin-1 delivery by a novel device suppressed experimentally-induced choroidal neovascularizationSevere uveitis in an HLA-B27-positive patient with ankylosing spondylitis.Golimumab as rescue therapy for refractory immune-mediated uveitis: a three-center experience.Immunopathogenesis of ocular Behçet's diseaseAn update on the use of biologic therapies in the management of uveitis in Behçet's disease: a comprehensive review.The use of biologic agents in the treatment of ocular manifestations of Behcet's disease.Autoimmune and autoinflammatory mechanisms in uveitis.Developments in the treatment of uveitis.Systemic therapies for inflammatory eye disease: past, present and futurePerspectives for TNF-alpha-targeting therapies.Emerging role of anti-tumor necrosis factor therapy in rheumatic diseasesLocal therapies for inflammatory eye disease in translation: past, present and futureUpdated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases (May 2002).Correlation between Ocular Manifestations and Their Complications as Opposed to Visual Acuity and Treatment in Behcet's Disease.Ileocecal ulcers accompanied by relapsing polychondritis: a case report.Difficult treatment issues in sarcoidosis.Overview of the use of the anti-TNF agent infliximab in chronic inflammatory diseases.Molecular targets in immune-mediated diseases: the case of tumour necrosis factor and rheumatoid arthritis.Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases (May 2003).Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004.Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005Systemic CD4(+) T cell phenotype and activation status in intermediate uveitis.Anti-TNF-alpha therapy for sight threatening uveitis.Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006.Managing the symptoms of Behçet's disease.Efficacy of infliximab in refractory Behçet's disease-associated and idiopathic posterior segment uveitis: a prospective, follow-up study of 50 patientsDevelopments in the treatment of juvenile arthritis.The utility of tumour necrosis factor blockade in orphan diseases.Tumour necrosis factor inhibitors: risks and benefits in patients with rheumatoid arthritis.Extraintestinal manifestations of Crohn's disease.Behçet's disease: a review.Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007A review of Campath in autoimmune disease: biologic therapy in the gray zone between immunosuppression and immunoablation.Infliximab for juvenile idiopathic arthritis-associated uveitis.Adalimumab for sight-threatening uveitis in Behçet's disease.
P2860
Q24671543-41D5304B-CFAB-44AA-A841-FB69AD037E62Q24675071-4409488C-5356-44CB-98AD-C6C1041F8F41Q24799647-CA1883E1-6B12-456B-982C-D9A22DB422E1Q24804631-0A92AE93-1487-41AE-A088-55866A38153AQ26777598-45FA1196-BB10-4047-BA75-792A2D0B5E6EQ28487648-5CAD18D6-31AB-4BF3-A04D-C0D43CDDA8B4Q33255239-4E1E4407-65A9-415C-8A54-6E00BA651AFCQ33757440-0B8FAB07-209F-4659-B713-4C6DABC33BF6Q33908937-A015BA4A-8735-4606-B48C-9C3097313D68Q33910781-721EFD3D-CB17-4CB4-B8F4-AEC291A873D5Q34220221-CFBC0F1E-9F5B-4856-8E29-8A52706AC7EAQ34294964-9C1184A1-CE78-4370-ACD7-5637DA5236B2Q34481964-23923EFB-E0AF-4DF9-A020-680555960F4EQ34687332-D4F16052-2EFA-46F0-B04B-FE7F88EB3724Q34731078-A1635B0A-E32C-48D6-B630-F9D4D182AC03Q34731307-14C19CB5-28E7-429C-AF0A-AA02BCE440BDQ34892662-9EBEC17D-B7A3-4B25-B50D-FD1134EA3D66Q34962946-A32A9390-1F89-4FF1-BA26-DAF8A5736AECQ35001001-72AE07D9-1038-4C79-ABC9-F7CD2895DE67Q35059131-C3C22B61-4D8F-45A3-841E-D4558077A054Q35067120-D88BE312-909D-4F40-8E9E-6C66BDC46851Q35116177-3E510341-308C-4081-9FAC-22E9D896A11FQ35216972-9753C86D-D70B-4610-8986-2C870514FB2BQ35553451-0494E7C7-B4AC-4893-A388-0B9D68ACF714Q35579352-65FAEDE9-A4DD-4B2F-851F-E87AE4858C91Q35579517-9FB5056C-77B5-4268-8108-035DC30B5248Q35591867-90170489-194A-4354-82A9-E043B1BDA936Q35593155-37FD03CF-A2C6-4AB6-9796-FCB00EA4DE55Q35638252-8ADDC211-CCF5-48CD-A2F6-1C89EA3F15A9Q35680592-4FE3C3BB-BFAF-4A89-A86A-4904B2E9E065Q35699360-B2743B63-1D76-46B2-BE1E-CA8828D9CB74Q35814399-8558EDB2-2560-43AC-9F66-41A61A05B73EQ35915996-6B922D00-698D-4C74-9AA4-731D9EA411C2Q35989499-442D4193-D573-449D-AEC7-052DBA088596Q36041720-B225220B-1523-4A8D-869A-CBE3CF8EC2AAQ36050822-765811DA-C663-41BA-A335-8EABCACD1EB5Q36171750-921876E7-3A4F-4CEB-926C-BBA9FE5B226BQ36194538-67D8729C-3CDB-479B-A226-947830668273Q36266391-9A614C10-E69E-4AB6-9E2D-9248EA5DBE1EQ36443513-5712B013-EEAD-4C2D-B650-A17ECCB31244
P2860
Effect of infliximab on sight-threatening panuveitis in Behçet's disease.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
Effect of infliximab on sight-threatening panuveitis in Behçet's disease.
@en
Effect of infliximab on sight-threatening panuveitis in Behçet's disease.
@nl
type
label
Effect of infliximab on sight-threatening panuveitis in Behçet's disease.
@en
Effect of infliximab on sight-threatening panuveitis in Behçet's disease.
@nl
prefLabel
Effect of infliximab on sight-threatening panuveitis in Behçet's disease.
@en
Effect of infliximab on sight-threatening panuveitis in Behçet's disease.
@nl
P2093
P1433
P1476
Effect of infliximab on sight-threatening panuveitis in Behçet's disease.
@en
P2093
C G Katsiari
N N Markomichelakis
P G Theodossiadis
P Kaklamanis
P P Sfikakis
P304
P356
10.1016/S0140-6736(01)05497-6
P407
P577
2001-07-01T00:00:00Z